WBRT for brain metastases from non-small cell lung cancer: for whom and when?-Contemporary point of view.

ABSTRACT: The incidence of brain metastases (BM) is estimated between 20% and 40% of patients with solid cancer. The most common cause of this failure is lung cancer, and in locally advanced non-small cell lung cancer (NSCLC) BM represent a common site of relapse in 30-55% cases. The basic criteria of therapeutic decision-making are based on the significant prognostic factors which are components of prognostic scores. The standard approach to treatment of BM from NSCLC include whole brain radiotherapy (WBRT) which is used as adjuvant modality after local therapy (surgery or stereotactic radiosurgery) or as primary treatment and it remains the primary modality of treatment for patients with multiple metastases. WBRT is also used in combination with systemic therapy. The aim of presented review of lit

SUBMITTER: Sas-Korczynska B 

PROVIDER: S-EPMC8182552 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature